Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Quantitative expression profile of PSGR in prostate cancer

Prostate Cancer and Prostatic Diseases volume 9, pages 56–61 (2006)Cite this article

Abstract

PSGR is a novel member of the G-protein-coupled olfactory receptor family. Our initial report showed predominant expression of the PSGR in human prostate gland and significant alterations of PSGR expression in primary prostate cancer (CaP) specimens. The aim of this study was to provide in-depth evaluations of the expression profile of PSGR in prostatic epithelial cells of CaP patients and to evaluate the association of PSGR expression characteristics with clinico-pathologic features. In total, 220 RNA specimens, from laser capture microdissected paired benign and malignant prostatic epithelial cells of 110 CaP patients, were analyzed for PSGR expression by quantitative real-time PCR. The differential expression of PSGR between the prostatic epithelial cells of malignant and benign glands was statistically significant (P<0.0001). Comparison of PSGR expression between paired benign and tumor cells revealed prostate tumor cell-specific overexpression in 67.2% of tumor specimens (74 of 110), decreased expression in 20.9% of tumor specimens (23 of 110) and no difference of PSGR expression between tumor and normal cells in 11.8% of specimens (13 of 110). In representative cases, PSGR expression patterns were independently confirmed by in situ RNA hybridization. The PSGR overexpression associated with higher percentage of pathologic stage, pT3, and a higher level of preoperative serum PSA. CaP cells of African-American CaP patients exhibited about two-fold increase of PSGR expression in comparison to the Caucasian American CaP patients. Strikingly high-percentage CaP cells overexpress PSGR warrants further studies of PSGR expression alterations to define subsets of CaPs.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E et al. Cancer statistics 2004. Can Cancer J Clin 2004; 54: 8–29.

    Article  Google Scholar 

  2. Small EJ . Update on the diagnosis and treatment of CaP. Curr Opin Oncol 1998; 10: 244–252.

    Article  CAS  Google Scholar 

  3. Krongrad A, Lai H, Lai S . Survival after radical prostatectomy. JAMA 1997; 278: 44–46.

    Article  CAS  Google Scholar 

  4. Garwick MB, Fair WR . Prostate Cancer. Scientific American, 1998, 75–83.

    Google Scholar 

  5. Augustus M, Moul JW, Srivastava S . The molecular phenotype of the malignant prostate. In: Srivastava S, Henson DE, Gazden A (eds). Molecular Pathology of Early Cancer. IOS press: Amsterdam, 1999; pp 321–340.

    Google Scholar 

  6. Xu LL, Stackhouse BG, Florence K, Zhang W, Shanmugam N, Sesterhenn IA et al. PSGR, a novel prostate-specific gene with homology to a G protein-coupled receptor, is overexpressed in prostate cancer. Cancer Res 2000; 60: 6568–6572.

    PubMed  CAS  Google Scholar 

  7. Mombaerts P . Seven-transmembrane proteins as odorant and chemosensory receptors. Science 1999; 286: 707–710.

    Article  CAS  Google Scholar 

  8. Xia C, Ma W, Wang F, Hua Sb, Liu M . Identification of a prostate specific G-protein coupled receptor in Prostate cancer. Oncogene 2001; 20: 5903–5907.

    Article  CAS  Google Scholar 

  9. Yuan TT, Toy P, McClary JA, Lin RJ, Miyamoto NG, Kretschmer PJ . Cloning and genetic characterization of an evolutionary conserved olfactory receptor that is differentially expressed across species. Gene 2001; 278: 41–51.

    Article  CAS  Google Scholar 

  10. Vanti WB, Nguyen T, Cheng R, Lynch KR, George SR, O’Dowd BF . Novel human G-protein-coupled receptors. Biochem Biophys Res Commun 2003; 305: 67–71.

    Article  CAS  Google Scholar 

  11. Simone NL, Bonner RF, Gillespie JW, Emmert-Buck MR, Liotta LA . Laser-capture microdissection: opening the microscopic frontier to molecular analysis. Trends Genet 1998; 14: 272–276.

    Article  CAS  Google Scholar 

  12. Best CJ, Emmert-Buck MR . Molecular profiling of tissue samples using laser capture microdissection. Expert Rev Mol Diagn 2001; 1: 53–60.

    Article  CAS  Google Scholar 

  13. Rubin MA . Use of laser capture microdissection, cDNA microarrays, and tissue microarrays in advancing our understanding of prostate cancer. J Pathol 2001; 195: 80–86.

    Article  CAS  Google Scholar 

  14. Sakr WA, Macoska JA, Benson P, Grignon DJ, Wolman SR, Pontes JE et al. Allelic loss in locally metastatic, multi-sampled prostate cancer. Cancer Res 1994; 54: 273–277.

    Google Scholar 

  15. Mirchandani D, Zheng J, Miller GJ, Ghosh AK, Shibata DK, Cote RJ et al. Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer. Am J Path 1995; 147: 92–101.

    PubMed  CAS  Google Scholar 

  16. Foster CS, Bostwick DG, Bonkhoff H, Damber JE, van der Kwast T, Montironi R et al. Cellular and molecular pathology of prostate cancer precursors. Scand J Urol Nephrol 2000; 205: 19–43.

    Article  Google Scholar 

  17. Isaacs W, De Marzo AD, Nelson WG . Focus on prostate cancer. Cancer Cell 2002; 2: 113–116.

    Article  CAS  Google Scholar 

  18. Bauer JJ, Moul JW, McLeod DG . Prostate cancer: diagnosis, treatment, and experience at one tertiary medical center, 1989 and 1994. Mil Med 1996; 161: 646–653.

    Article  CAS  Google Scholar 

  19. Heidenberg HB, Bauer JJ, McLeod DG, Moul JW, Srivastava S . The role of p53 tumor suppressor gene in CaP: a possible biomarker? Urology 1996; 48: 971–979.

    Article  CAS  Google Scholar 

  20. Bussemakers MJ . Changes in gene expression and targets for therapy. Eur Uro 1999; 35: 408–412.

    Article  CAS  Google Scholar 

  21. Lijovic M, Fabiani ME, Bader J, Frauman AG . Prostate cancer: are new prognostic markers on the horizon? Prostate Cancer and Prostatic Dis 2000; 3: 62–65.

    Article  CAS  Google Scholar 

  22. Feroze-Merzoug F, Schober MS, Chen YQ . Molecular profiling in prostate cancer. Cancer Metast Rev 2001; 20: 165–171.

    Article  CAS  Google Scholar 

  23. Xu LL, Shanmugam N, Segawa T, Sesterhenn IA, McLeod DG, Moul JW et al. A novel androgen-regulated gene, PMEPA1, located on chromosome 20q13 exhibits high level expression in prostate. Genomics 2000; 66: 257–263.

    Article  CAS  Google Scholar 

  24. Srikantan V, Zou Z, Petrovics G, Xu L, Augustus M, Davis L et al. PCGEM1: a Novel Prostate Specific Gene is Overexpressed in prostate cancer. Proc Nat Acad Sci USA 2000; 97: 12216–12221.

    Article  CAS  Google Scholar 

  25. Petrovics G, Zhang W, Makarem M, Street JP, Connelly R, Sun L et al. Elevated expression of PCGEM1, a prostate-specific gene with cell growth promoting function, is associated with high-risk prostate cancer patients. Oncogene 2004; 23: 605–611.

    Article  CAS  Google Scholar 

  26. Weng J, Wang J, Cai Y, Stafford LJ, Mitchell D, Ittmann M, Liu M . Increased expression of prostate-specific G-protein-coupled receptor in human prostate intraepithelial neoplasia and prostate cancers. Int J Cancer 2005; 113: 811–818.

    Article  CAS  Google Scholar 

  27. Morgan TO, Jacobsen SJ, McCarthy WF, Jacobson DJ, McLeod DG, Moul JW . Age-specific reference ranges for prostate-specific antigen in black men. N Engl J Med 1996; 335: 304–310.

    Article  CAS  Google Scholar 

  28. Abdalla I, Ray P, Vijayakumar S . Race and serum prostate-specific antigen levels: current status and future directions. Semin Urol Oncol 1998; 16: 207–213.

    PubMed  CAS  Google Scholar 

  29. Yang G, Addai J, Ittmann M, Wheeler TM, Thompson TC . Elevated caveolin-1 levels in African-American versus white-American prostate cancer. Clin Cancer Res 2000; 6: 3430–3433.

    PubMed  CAS  Google Scholar 

  30. Winter DL, Hanlon AL, Raysor SL, Watkins-Bruner D, Pinover WH, Hanks GE et al. Plasma levels of IGF-1, IGF-2, and IGFBP-3 in white and African-American men at increased risk of prostate cancer. Urology 2001; 58: 614–618.

    Article  CAS  Google Scholar 

  31. Xu J, Zheng SL, Komiya A, Mychaleckyj JC, Isaacs SD, Hu JJ et al. Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet 2002; 32: 321–325.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This study is supported by a Grant from US Army Medical Research and Materiel Command (DAMD17-02-1-0065). The opinions and assertions contained herein are the private views of the authors and are not to be considered as reflecting the views of the US Army or the Department of Defense.

Author information

Authors and Affiliations

  1. Department of Surgery, Center for Prostate Disease Research (CPDR), Uniformed Services University of the Health Sciences, Rockville, MD, USA

    L L Xu, C Sun, G Petrovics, M Makarem, B Furusato, W Zhang, D G McLeod, L Sun, J W Moul & S Srivastava

  2. Department of Genitourinary Pathology, Armed Forces Institute of Pathology (AFIP), Washington, DC, USA

    I A Sesterhenn

  3. Urology Service, Walter Reed Army Medical Center, Washington, DC, USA

    D G McLeod & J W Moul

Authors
  1. L L Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G Petrovics
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Makarem
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B Furusato
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. W Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. I A Sesterhenn
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. D G McLeod
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. L Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. J W Moul
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. S Srivastava
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S Srivastava.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Xu, L., Sun, C., Petrovics, G. et al. Quantitative expression profile of PSGR in prostate cancer. Prostate Cancer Prostatic Dis 9, 56–61 (2006). https://doi.org/10.1038/sj.pcan.4500836

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.pcan.4500836

Keywords

This article is cited by

Search

Advanced search

Quick links